| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester manufacturers
- Arhalofenate
-
- $56.00
-
2026-08-30
- CAS:24136-23-0
- Purity: 99.62%
- Supply Ability: 10g
|
| | 4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester Basic information |
| Product Name: | 4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester | | Synonyms: | MBX 102;JNJ 39659100;(aR)-4-Chloro-a-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester;Benzeneacetic acid, 4-chloro-α-[3-(trifluoromethyl)phenoxy]-, 2-(acetylamino)ethyl ester, (αR)-;4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester;Benzeneaceticacid,4-chloro-α-[3-(trifluoromethyl)phenoxy]-,2-(acetylamino)ethylester,(αR)-;MBX-102 >=98% (HPLC);JNJ-39659100,MBX102,Arhalofenate,Inhibitor,MBX-102,inhibit,PPAR,Peroxisome proliferator-activated receptors,JNJ39659100 | | CAS: | 24136-23-0 | | MF: | C19H17ClF3NO4 | | MW: | 415.79 | | EINECS: | | | Product Categories: | | | Mol File: | 24136-23-0.mol | ![4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester Structure](CAS2/GIF/24136-23-0.gif) |
| | 4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester Chemical Properties |
| Boiling point | 551.1±50.0 °C(Predicted) | | density | 1.331 | | storage temp. | 2-8°C | | solubility | DMSO: ≥35mg/mL | | pka | 15.32±0.46(Predicted) | | form | powder | | color | white to tan | | InChI | 1S/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/t17-/m1/s1 | | InChIKey | BJBCSGQLZQGGIQ-QGZVFWFLSA-N | | SMILES | FC(F)(F)c1cc(ccc1)O[C@H](c2ccc(cc2)Cl)C(=O)OCCNC(=O)C |
| Hazard Codes | T,N | | Risk Statements | 25-36-50/53 | | Safety Statements | 26-45-60-61 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral
Aquatic Acute 1
Eye Irrit. 2 |
| | 4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester Usage And Synthesis |
| Uses | MBX 102 is used as a new medication to treat and prevent acute gouty flares, also used as URAT 1 inhibitor. | | Biological Activity | MBX-102 has a potent transrepression effect on PPARγ. It is an oral glucose-reducing agent and also has insulin-sensitizing properties. It is useful as treatment for type 2 diabetes. MBX-102 also lowers triglycerides in a PPARα-independent manner.', 'MBX-102 is a selective PPAR modulator (SPPARM) and has been shown to inhibit phosphorylation of PPARγ. MBX-102 is converted to the active form, MBX-102 acid, in vivo. | | in vivo | Arhalofenate (MBX 102) (100 mg/kg, p.o.) significantly increases the glucose infusion rate and decreases hepatic glucose output in the clamped state in Zucker Diabetic Fatty (ZDF) rats. Arhalofenate (MBX 102) (60 mg/kg) leads to a dramatic decrease in plasma and also results in a dose-dependent, significant decrease in the insulin resistance indexinsulin levels[1]. Arhalofenate (MBX 102) (100 mg/kg, p.o.) significantly decreases triglyceride, free fatty acid, and cholesterol levels in ZDF rats. MBX-102 significantly reduces fasting blood glucose, confirming that Arhalofenate (MBX 102) is an efficacious antidiabetic agent. Arhalofenate (MBX 102) (100 mg/kg, p.o.) also significantly lowers fasting plasma insulin, and robustly decreases fasting plasma triglycerides after 32 days of treatment in Zucker Fatty (ZF) rats[2]. | | IC 50 | PPAR-γ |
| | 4-Chloro-alpha-[3-(trifluoromethyl)phenoxy]benzeneacetic acid 2-(acetylamino)ethyl ester Preparation Products And Raw materials |
|